EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO

Christine L Chan iD, Meghan Shirley Bezerra, Darko Stefanovski, Robert J Gallop, Rachel Walega, Scott H Donaldson, Carla A Frederick, Steven D Freedman, Daniel Gelfond, Lucas R Hoffman, Michael R Narkewicz, Steven M Rowe und 5 weitere

The Journal of Clinical Endocrinology & Metabolism · 07.08.2025 · 110 (9) · 2674-2684

DOI: 10.1210/clinem/dgae857 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.12.2024. Verfasst von Christine L Chan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO 80045, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Insulin Secretion, Blood Glucose. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Diabetes Research Center, University of Pennsylvania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elexacaftor/tezacaftor/ivacaftor (ETI) is a highly effective therapy that improves lung disease in people with cystic fibrosis (pwCF), but its effect on glucose tolerance and insulin secretion is unclear.

Methods

PROMISE is a multicenter prospective, observational study of ETI in pwCF ≥12 years and at least one F508del allele. The PROMISE Endocrine substudy (PROMISE-ENDO) enrolled participants at 10 CF Centers where hemoglobin A1c (HbA1c) was collected and 3-hour oral glucose tolerance tests (OGTT) conducted to examine glucose tolerance, glucose excursions, and insulin secretory rates (deconvolution of C-peptide) and sensitivity (oral minimal model) prior to ETI and 12 to 18 months and 24-30 months following ETI initiation. Longitudinal mixed effects models were used to test within-subject ETI effects.

Results

At baseline, 79 participants completed OGTTs (39 [49%] male, median [IQR] age 19.6 [14.7, 27.3] years, BMI z-score 0.12 [−0.51, 0.65]). At 12-18 months n = 68 and at 24-30 months n = 58 completed OGTTs. At 24-30 months, fasting glucose (mg/dL) decreased (94 [92, 96] to 90 [88, 93], P = .02) in the subset not on insulin therapy (n = 61), but no differences in 1-hour or 2-hour glucose were found. HbA1c decreased from 5.8% (5.6%, 5.9%) to 5.5% (5.4%, 5.6%), P < .001 by 24-30 months. Although insulin sensitivity (mU/L−1 min−1) decreased (8.4 [7.2, 9.5] vs 6.8 [5.8, 7.9], P = .03), no changes in oral disposition index were found, P = .14.

Conclusion

After 2 years of ETI, fasting glucose and HbA1c showed modest decreases. Glucose tolerance varied, and overall measures of insulin secretion did not deteriorate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsInsulin SecretionBlood GlucoseQuinolonesInsulinBenzodioxolesIndolesPyridinesPyrrolidinesPyrazolesHumansMaleFemaleAdultDrug CombinationsYoung AdultGlucose Tolerance TestAdolescentGlycated HemoglobinProspective StudiesChloride Channel AgonistsQuinolines

Stichwörter der Autor:innen

cystic fibrosiscystic fibrosis–related diabeteselexacaftor/tezacaftor/ivacaftorhemoglobin A1cmodulatororal glucose tolerance test

Substanzen

AminophenolsBlood GlucoseDrug CombinationsQuinolonesInsulinBenzodioxolesIndolesGlycated HemoglobinPyridinesPyrrolidines

Autor:innen und Institutionen

  • Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO 80045, USA.
  • Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, PA 19104, USA.
  • Department of Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
  • Department of Medicine, Jacobs School of Medicine and Biomedical Sciences of the University of Buffalo, Buffalo, NY 14203, USA.

ORCID-Profile: Christine L Chan

Förderung

  • NIDDK NIH HHS
  • Diabetes Research Center
  • University of Pennsylvania
  • CF Foundation

Zitieren

APA

Chan, C. L., Shirley Bezerra, M., Stefanovski, D., Gallop, R. J., Walega, R., Donaldson, S. H., Frederick, C. A., Freedman, S. D., Gelfond, D., Hoffman, L. R., Narkewicz, M. R., Rowe, S. M., Sagel, S. D., Schwarzenberg, S. J., Solomon, G. M., Stalvey, M. S., & Kelly, A. (2025). Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. The Journal of Clinical Endocrinology & Metabolism, 110(9), 2674-2684. https://doi.org/10.1210/clinem/dgae857

Vancouver

Chan CL, Shirley Bezerra M, Stefanovski D, Gallop RJ, Walega R, Donaldson SH, et al. Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO. The Journal of Clinical Endocrinology & Metabolism. 2025;110(9):2674-2684. doi:10.1210/clinem/dgae857

BibTeX
@article{Chan2025,
  author = {Chan, Christine L and Shirley Bezerra, Meghan and Stefanovski, Darko and Gallop, Robert J and Walega, Rachel and Donaldson, Scott H and Frederick, Carla A and Freedman, Steven D and Gelfond, Daniel and Hoffman, Lucas R and Narkewicz, Michael R and Rowe, Steven M and Sagel, Scott D and Schwarzenberg, Sarah Jane and Solomon, George M and Stalvey, Michael S and Kelly, Andrea},
  title = {Glycemia and Insulin Secretion in Cystic Fibrosis 2 Years After Elexacaftor/Tezacaftor/Ivacaftor: PROMISE-ENDO},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {9},
  pages = {2674--2684},
  doi = {10.1210/clinem/dgae857}
}
Kostenlos starten →